Loading clinical trials...
Loading clinical trials...
Randomized, Open-Label, Active-Controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa
Conditions
Interventions
Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.
Tobramycin inhalation solution using a PARI LC® Plus nebulizer.
Locations
62
Austria
Vienna, Austria
Brussels, Belgium
Ghent, Belgium
Leuven, Belgium
Pleven, Bulgaria
Plovdiv, Bulgaria
Start Date
February 29, 2012
Primary Completion Date
June 1, 2013
Completion Date
September 18, 2013
Last Updated
June 16, 2020
NCT06319235
NCT01563263
Lead Sponsor
Insmed Incorporated
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions